Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Other Operating Expenses (2024 - 2026)

ArriVent BioPharma has reported Other Operating Expenses over the past 3 years, most recently at -$2.3 million for Q1 2026.

  • Quarterly results put Other Operating Expenses at -$2.3 million for Q1 2026, down 7.44% from a year ago — trailing twelve months through Mar 2026 was -$8.9 million (down 17.2% YoY), and the annual figure for FY2025 was -$8.8 million, down 22.77%.
  • Other Operating Expenses reached -$2.3 million in Q1 2026 per AVBP's latest filing, down from -$2.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$1.5 million in Q4 2024 and bottomed at -$2.4 million in Q2 2025.
  • Median Other Operating Expenses over the past 3 years was -$2.1 million (2024), compared with a mean of -$2.0 million.
  • Peak annual rise in Other Operating Expenses hit 7.37% in 2025, while the deepest fall reached 54.86% in 2025.
  • Over 3 years, Other Operating Expenses stood at -$1.5 million in 2024, then plummeted by 54.86% to -$2.3 million in 2025, then dropped by 2.21% to -$2.3 million in 2026.
  • Business Quant data shows Other Operating Expenses for AVBP at -$2.3 million in Q1 2026, -$2.3 million in Q4 2025, and -$1.9 million in Q3 2025.